Jason Busse's guest appearances

Jason Busse

Roy Green Show

Kelly Cutrara

OE OrthoPod

OrthoJOE

Zain Chagla

Asheesh Bedi

Pete Townshend

Antonia Chen

Darryl Yardley

Sham Surgery

Lehana Thabane

Joel Boyd

Kent Anderson

Javad Parvizi

Chris Raynor

Flavia Borges

PJ Devereaux

Martha Oner

Brad Petrisor

OwlTail

In this episode, Mo and Marc are joined by special guest Jason Busse (Professor in the Department of Anesthesia at McMaster University, Director of the National Pain Centre, and Associate Director of the Michael G. DeGroote Centre for Medicinal Cannabis Research), in a discussion on research into the relative effectiveness and harms associated with various types of opioids, cannabinoids, and psychedelics in the treatment of chronic pain.   Links:  Noori A, Sadeghirad B, Wang L, Siemieniuk RAC, Shokoohi M, Kum E, Jeddi M, Montoya L, Hong PJ, Zhou E, Couban RJ, Juurlink DN, Thabane L, Bhandari M, Guyatt GH, Busse JW. Comparative benefits and harms of individual opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised trials. Br J Anaesth. 2022 Sep;129(3):394-406. doi: 10.1016/j.bja.2022.05.031. Epub 2022 Jul 9. PMID: 35817616. https://bit.ly/3KOtVat     Kane RL, Bershadsky B, Rockwood T, Saleh K, Islam NC. Visual Analog Scale pain reporting was standardized. J Clin Epidemiol. 2005 Jun;58(6):618-23. doi: 10.1016/j.jclinepi.2004.11.017. PMID: 15878476. https://bit.ly/3BrSIyd     Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, Agoritsas T, Akl EA, Carrasco-Labra A, Cooper L, Cull C, da Costa BR, Frank JW, Grant G, Iorio A, Persaud N, Stern S, Tugwell P, Vandvik PO, Guyatt GH. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017 May 8;189(18):E659-E666. doi: 10.1503/cmaj.170363. PMID: 28483845; PMCID: PMC5422149. https://bit.ly/3QhqY3f    Subspecialties:  Basic Science Education and Training Ethics Foot &amp; Ankle Hand &amp; Wrist Hip Knee Oncology Orthopaedic Essentials Pain Management Rehabilitation Pediatrics Spine Shoulder Elbow Sports Medicine Trauma

In this episode, Mo and Marc are joined by special guest Jason Busse (Professor in the Department of Anesthesia at McMaster University, Director of the National Pain Centre, and Associate Director of the Michael G. DeGroote Centre for Medicinal Cannabis Research), in a discussion on research into the relative effectiveness and harms associated with various types of opioids, cannabinoids, and psychedelics in the treatment of chronic pain. Links: <ul> <li>Noori A, Sadeghirad B, Wang L, Siemieniuk RAC, Shokoohi M, Kum E, Jeddi M, Montoya L, Hong PJ, Zhou E, Couban RJ, Juurlink DN, Thabane L, Bhandari M, Guyatt GH, Busse JW. Comparative benefits and harms of individual opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised trials. Br J Anaesth. 2022 Sep;129(3):394-406. doi: 10.1016/j.bja.2022.05.031. Epub 2022 Jul 9. PMID: 35817616. <a href="https://bit.ly/3KOtVat" rel="noopener nofollow" target="_blank">https://bit.ly/3KOtVat</a></li> </ul> <ul> <li>Kane RL, Bershadsky B, Rockwood T, Saleh K, Islam NC. Visual Analog Scale pain reporting was standardized. J Clin Epidemiol. 2005 Jun;58(6):618-23. doi: 10.1016/j.jclinepi.2004.11.017. PMID: 15878476. <a href="https://bit.ly/3BrSIyd" rel="noopener nofollow" target="_blank">https://bit.ly/3BrSIyd</a></li> </ul> <ul> <li>Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, Agoritsas T, Akl EA, Carrasco-Labra A, Cooper L, Cull C, da Costa BR, Frank JW, Grant G, Iorio A, Persaud N, Stern S, Tugwell P, Vandvik PO, Guyatt GH. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017 May 8;189(18):E659-E666. doi: 10.1503/cmaj.170363. PMID: 28483845; PMCID: PMC5422149. <a href="https://bit.ly/3QhqY3f" rel="noopener nofollow" target="_blank">https://bit.ly/3QhqY3f</a></li> </ul> Subspecialties: <ul> <li>Basic Science</li> <li>Education and Training</li> <li>Ethics</li> <li>Foot &amp; Ankle</li> <li>Hand &amp; Wrist</li> <li>Hip</li> <li>Knee</li> <li>Oncology</li> <li>Orthopaedic Essentials</li> <li>Pain Management</li> <li>Rehabilitation</li> <li>Pediatrics</li> <li>Spine</li> <li>Shoulder</li> <li>Elbow</li> <li>Sports Medicine</li> <li>Trauma</li></ul>

Chronic Pain Research, with special guest Jason Busse

Orthopaedic patients are increasingly using cannabinoids for pain relief, but there is a lack of evidence-based data on this topic. In this episode, Marc and Mo are joined by special guest Jason Busse (Associate Professor in the Department of Anesthesia at McMaster University, Director of the National Pain Centre, and Associate Director of the Michael G. DeGroote Centre for Medicinal Cannabis Research) in an illuminating discussion on the issues, opportunities, and challenges related to orthopaedic research into the use of cannabinoids. Some of the questions covered during the discussion include:    What are the most popular claims among cannabis proponents? What evidence is there to support these claims? Is there a causal relationship between cannabinoid use and decreased use of opioids and other prescription medications (i.e., a “substitution effect”)?  Much of the current evidence on cannabinoids is observational and anecdotal. What can we learn from this evidence, and how can such information inform future research?  What are the possible sources of funding for such research? What legal and regulatory hurdles must be overcome in order to allow us to perform properly designed RCTs into this topic? What challenges are faced by physicians when asked by patients about cannabinoids? What research is being done from the patient perspective? What is the roadmap for the future? How we will obtain quality evidence that will help clinicians and their patients to make decisions that are consistent with their values and preferences?     OrthoJOE Mailbag: feedback, comments, and suggestions from our audience can be sent to orthojoe@jbjs.org   Links:  Yun C, Haleem MS, Jeong S, Oyer MA, Driscoll AJ, Chang KY, Yun J, Paul J, Lubbe RJ, Stock SR, Hsu WK, Hsu EL. Effect of Postoperative Analgesic Exposure to the Cannabinoid Receptor Agonist WIN55 on Osteogenic Differentiation and Spinal Fusion in Rats. J Bone Joint Surg Am. 2021 Jun 2;103(11):984-991. doi: 10.2106/JBJS.20.00573. PMID: 33759484. Link. Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631. PMID: 29768152. Link. Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. PMID: 28538134. Link.  Ng JY, Gilotra K, Usman S, Chang Y, Busse JW. Attitudes toward medical cannabis among family physicians practising in Ontario, Canada: a qualitative research study. CMAJ Open. 2021 Apr 13;9(2):E342-E348. doi: 10.9778/cmajo.20200187. PMID: 33849983; PMCID: PMC8084545. Link. NICE Guidelines on cannabis-based medicinal products: https://www.nice.org.uk/guidance/ng144

Orthopaedic patients are increasingly using cannabinoids for pain relief, but there is a lack of evidence-based data on this topic. In this episode, Marc and Mo are joined by special guest Jason Busse (Associate Professor in the Department of Anesthesia at McMaster University, Director of the National Pain Centre, and Associate Director of the Michael G. DeGroote Centre for Medicinal Cannabis Research) in an illuminating discussion on the issues, opportunities, and challenges related to orthopaedic research into the use of cannabinoids. Some of the questions covered during the discussion include: <ul> <li>What are the most popular claims among cannabis proponents? What evidence is there to support these claims?</li> <li>Is there a causal relationship between cannabinoid use and decreased use of opioids and other prescription medications (i.e., a “substitution effect”)? </li> <li>Much of the current evidence on cannabinoids is observational and anecdotal. What can we learn from this evidence, and how can such information inform future research? </li> <li>What are the possible sources of funding for such research?</li> <li>What legal and regulatory hurdles must be overcome in order to allow us to perform properly designed RCTs into this topic?</li> <li>What challenges are faced by physicians when asked by patients about cannabinoids?</li> <li>What research is being done from the patient perspective?</li> <li>What is the roadmap for the future? How we will obtain quality evidence that will help clinicians and their patients to make decisions that are consistent with their values and preferences? </li> </ul> OrthoJOE Mailbag: feedback, comments, and suggestions from our audience can be sent to <a href="mailto:orthojoe@jbjs.org">orthojoe@jbjs.org</a> Links: <ul> <li>Yun C, Haleem MS, Jeong S, Oyer MA, Driscoll AJ, Chang KY, Yun J, Paul J, Lubbe RJ, Stock SR, Hsu WK, Hsu EL. Effect of Postoperative Analgesic Exposure to the Cannabinoid Receptor Agonist WIN55 on Osteogenic Differentiation and Spinal Fusion in Rats. J Bone Joint Surg Am. 2021 Jun 2;103(11):984-991. doi: 10.2106/JBJS.20.00573. PMID: 33759484. <a href="https://jbjs.org/reader.php?id=209165&amp;rsuite_id=2805232&amp;native=1&amp;source=The_Journal_of_Bone_and_Joint_Surgery/103/11/984/fulltext&amp;topics=bs#info" rel="nofollow" target="_blank">Link.</a></li> <li>Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631. PMID: 29768152. <a href="https://www.nejm.org/doi/full/10.1056/nejmoa1714631" rel="nofollow" target="_blank">Link.</a></li> <li>Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. PMID: 28538134. <a href="https://www.nejm.org/doi/full/10.1056/nejmoa1611618" rel="nofollow" target="_blank">Link.</a> </li> <li>Ng JY, Gilotra K, Usman S, Chang Y, Busse JW. Attitudes toward medical cannabis among family physicians practising in Ontario, Canada: a qualitative research study. CMAJ Open. 2021 Apr 13;9(2):E342-E348. doi: 10.9778/cmajo.20200187. PMID: 33849983; PMCID: PMC8084545. <a href="http://cmajopen.ca/content/9/2/E342.long" rel="nofollow" target="_blank">Link.</a></li> <li>NICE Guidelines on cannabis-based medicinal products: <a href="https://www.nice.org.uk/guidance/ng144" rel="nofollow" target="_blank">https://www.nice.org.uk/guidance/ng144</a></li></ul>

Cannabinoids in Orthopaedic Research (with special guest Jason Busse)

Dr. Jason Busse is an Associate Professor in the Departments of Anesthesia and Clinical Epidemiology &amp; Biostatistics, McMaster University. He is the co-Principle Investigator for the TRUST trial, one of the world’s largest orthopedic randomized controlled trials.TrainingDr. Busse completed an MSc in Medical and Molecular Genetics at the University of Toronto, a Doctorate in Chiropractic at CMCC, training in Cognitive Behavioral Therapy at McMaster University, and a PhD in Health Research Methodology at McMaster University.Dr. Busse has been active clinically in the management of disability secondary to chronic pain and other medically unexplained syndromes since 1999 and currently serves as the Clinical Director for Prisma Health Canada – a private company that manages chronic claimants (5+ years on disability) referred by private disability insurers. From 2001 to 2010 Dr. Busse was the Director of the Complex Claims Division for ATF Canada, a private company that provided assessment and treatment for patients in receipt of long-term disability benefits.ResearchDr. Busse has published over 150 peer-reviewed articles in scientific journals with a focus on chronic pain, orthopedic trauma, insurance medicine and methodological research. In 2011 Dr. Busse co-formed the evidence-based insurance medicine research group, an international collaboration with members from McMaster University, the University Medical Center Groningen, and the Academy of Swiss Insurance Medicine. He is a Director of the Cochrane Insurance Medicine Field Group (http://insuremed.cochrane.org/our-team). Current research projects include:FORESITE– a prospective cohort to establish factors associated with persistent post-surgical pain following heart surgeryUpdate and revision of the Canadian Guideline regarding opioids for chronic non-cancer painTeaching and Promotion of Evidence-Based Clinical PracticeSince 2011, Dr. Busse has been a tutor for the McMaster Evidence-Based Clinical Practice workshop, and an editor for the Newsletter of the International Society for Evidence-Based Health Care since 2009.Awards and Honours2015:  McMaster University, HRM Mentoring/Supervision Award in the Full-Time/Joint Category2010: Outstanding Thesis Award, McMaster University, Faculty of Health Sciences Graduate Programs2009:  New Investigator Award, Canadian Institute of Health Research2003:  PhD Training Fellowship, Canadian Institute of Health Research

Dr. Jason Busse is an Associate Professor in the Departments of Anesthesia and Clinical Epidemiology &amp; Biostatistics, McMaster University. He is the co-Principle Investigator for the TRUST trial, one of the world’s largest orthopedic randomized controlled trials. Training Dr. Busse completed an MSc in Medical and Molecular Genetics at the University of Toronto, a Doctorate in Chiropractic at CMCC, training in Cognitive Behavioral Therapy at McMaster University, and a PhD in Health Research Methodology at McMaster University. Dr. Busse has been active clinically in the management of disability secondary to chronic pain and other medically unexplained syndromes since 1999 and currently serves as the Clinical Director for Prisma Health Canada – a private company that manages chronic claimants (5+ years on disability) referred by private disability insurers. From 2001 to 2010 Dr. Busse was the Director of the Complex Claims Division for ATF Canada, a private company that provided assessment and treatment for patients in receipt of long-term disability benefits. Research Dr. Busse has published over 150 peer-reviewed articles in scientific journals with a focus on chronic pain, orthopedic trauma, insurance medicine and methodological research. In 2011 Dr. Busse co-formed the evidence-based insurance medicine research group, an international collaboration with members from McMaster University, the University Medical Center Groningen, and the Academy of Swiss Insurance Medicine. He is a Director of the Cochrane Insurance Medicine Field Group (<a href="http://insuremed.cochrane.org/our-team" rel="nofollow" target="_blank">http://insuremed.cochrane.org/our-team</a>). Current research projects include: FORESITE– a prospective cohort to establish factors associated with persistent post-surgical pain following heart surgery Update and revision of the Canadian Guideline regarding opioids for chronic non-cancer pain Teaching and Promotion of Evidence-Based Clinical Practice Since 2011, Dr. Busse has been a tutor for the McMaster Evidence-Based Clinical Practice workshop, and an editor for the Newsletter of the International Society for Evidence-Based Health Care since 2009. Awards and Honours 2015:  McMaster University, HRM Mentoring/Supervision Award in the Full-Time/Joint Category 2010: Outstanding Thesis Award, McMaster University, Faculty of Health Sciences Graduate Programs 2009:  New Investigator Award, Canadian Institute of Health Research 2003:  PhD Training Fellowship, Canadian Institute of Health Research

In Conversation with Dr. Jason Busse